A research team led by MSK physician-scientist Dr. Piro Lito discovered that certain inhibitors can short-circuit the out-of-control signaling caused by mutations that fuel cancer growth. Each year, ...
The RAS family commonly drives the growth and survival of human cancers. Mutations in KRAS, NRAS, and HRAS occur in approximately 20% of all human cancers, including solid tumors, such as pancreatic, ...
Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with ...
Zacks Investment Research on MSN
Erasca stock surges 42% in a week: Here's what you should know
Shares of Erasca ERAS soared 41.5% in a week. The massive gain was observed after the company announced encouraging early clinical data from the phase I study of its investigational candidate, ...
Preclinical study offers foundation for a combination strategy in future clinical trials In this study, the researchers used RAS(ON) multi-selective inhibitors, the investigational agent daraxonrasib ...
Breakthrough Therapy Designation granted to zoldonrasib for the treatment of adult patients with KRAS G12D-mutated locally ...
Two companion studies published in Cancer Research from scientists at Moffitt Cancer Center identify distinct but complementary approaches to overcoming drug resistance in KRAS G12C–mutant non-small ...
Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC, with a strong therapeutic profile and potential for high returns if approved. Onvansertib's Phase II ...
KRASG12C-targeted therapies like sotorasib and adagrasib have been approved, but resistance challenges persist, necessitating further research into RAS(ON) therapies. Revolution Medicines is ...
RVMD stays a Strong Buy as RAS inhibitor trials advance; phase 3 RASolute-302 is a key 2026 catalyst. Read the latest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback